Senior Scientist
Merck & Co, Inc
Rahway, Pennsylvania
Habib Sistani attained his PhD in Chemistry from Temple University in 2019, specializing in the enhancement of sensitivity, reproducibility, and ease of analysis of the laser electrospray mass spectrometry technique. Following his graduation, Habib gained valuable experience at Eurofins c/o Janssen Pharmaceuticals, where he was involved in protein separations and characterization projects that employed separations-based techniques in conjunction with ultra-high resolution mass spectrometry (LC-MS).
Habib joined the regulated BA group at Merck in 2022, where he currently plays a pivotal role in the development and characterization of LC-MS based assays. These assays are essential for measuring drug levels in biological matrices, thus supporting GLP tox and Phase 1-3 clinical programs encompassing both small and large molecule modalities. One of Habib's primary scientific interests lies in exploring innovative solutions to complex questions. Additionally, he specializes in the application of hybrid LC-MS assays to address unique problems and enhance LBA workflows, as well as the bioanalysis of cyclic peptides.
Disclosure information not submitted.
Investigating Apparent Accumulation of Therapeutic A Upon Repeat Dosing
Monday, October 21, 2024
3:00 PM – 3:15 PM MT